Top

Published in:

01-11-2009 | Brief report

Genetic variants in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome

Authors: Jinyun Chen, Carol J. Etzel, Christopher I. Amos, Qing Zhang, Nancy Viscofsky, Noralane M. Lindor, Patrick M. Lynch, Marsha L. Frazier

Published in: Cancer Causes & Control | Issue 9/2009

Abstract

Purpose

Lynch syndrome is an autosomal dominant syndrome of familial malignancies resulting from germ line mutations in DNA mismatch repair (MMR) genes. Our goal was to take a pathway-based approach to investigate the influence of polymorphisms in cell cycle-related genes on age of onset for Lynch syndrome using a tree model.

Experimental design

We evaluated polymorphisms in a panel of cell cycle-related genes (AURKA, CDKN2A, TP53, E2F2, CCND1, TP73, MDM2, IGF1, and CDKN2B) in 220 MMR gene mutation carriers from 129 families. We applied a novel statistical approach, tree modeling (Classification and Regression Tree), to the analysis of data on patients with Lynch syndrome to identify individuals with a higher probability of developing colorectal cancer at an early age and explore the gene–gene interactions between polymorphisms in cell cycle genes.

Results

We found that the subgroup with CDKN2A C580T wild-type genotype, IGF1 CA-repeats ≥19, E2F2 variant genotype, AURKA wild-type genotype, and CCND1 variant genotype had the youngest age of onset, with a 45-year median onset age, while the subgroup with CDKN2A C580T wild-type genotype, IGF1 CA-repeats ≥19, E2F2 wild-type genotype, and AURKA variant genotype had the latest median age of onset, which was 70 years. Furthermore, we found evidence of a possible gene–gene interaction between E2F2 and AURKA genes related to CRC age of onset.

Conclusions

Polymorphisms in these cell cycle-related genes work together to modify the age at the onset of CRC in patients with Lynch syndrome. These studies provide an important part of the foundation for development of a model for stratifying age of onset risk among those with Lynch syndrome.

Peltomaki P, Vasen H (2004) Mutations associated with HNPCC predisposition—update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 20:269–276PubMed

Lindor NM, Petersen GM, Hadley DW et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. Jama 296:1507–1517CrossRefPubMed

Lynch HT, Boland CR, Gong G et al (2006) Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet 14:390–402CrossRefPubMed

Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214–218CrossRefPubMed

Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML (2000) Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 60:249–252PubMed

Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML (2004) p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 10:5845–5849CrossRefPubMed

Zecevic M, Amos CI, Gu X et al (2006) IGF1 gene polymorphism and risk for hereditary nonpolyposis colorectal cancer. J Natl Cancer Inst 98:139–143PubMedCrossRef

Chen J, Sen S, Amos CI et al (2007) Association between Aurora-A kinase polymorphisms and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Mol Carcinog 46:249–256CrossRefPubMed

Reeves SG, Rich D, Meldrum CJ et al (2008) IGF1 is a modifier of disease risk in hereditary non-polyposis colorectal cancer. Int J Cancer 123:1339–1343CrossRefPubMed

10.

Talseth BA, Ashton KA, Meldrum C et al (2008) Aurora-A and Cyclin D1 polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 122:1273–1277CrossRefPubMed

11.

Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ (2006) Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53. Int J Cancer 118:2479–2484CrossRefPubMed

12.

Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432:316–323CrossRefPubMed

13.

Li G, Wang LE, Chamberlain RM, Amos CI, Spitz MR, Wei Q (2004) p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res 64:6863–6866CrossRefPubMed

14.

Ruijs MW, Schmidt MK, Nevanlinna H et al (2007) The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 15:110–114CrossRefPubMed

15.

Sauroja I, Smeds J, Vlaykova T et al (2000) Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosom Cancer 28:404–414.ICrossRefPubMed

16.

Breiman L, Friedman JH, Olshen RA, Stone CJ (1984) Classification and regression trees. Wadsworth, Belmont

17.

Zhang H, Singer B (1999) Recursive partitioning in the health sciences. Springer, New York

18.

LeBlanc M, Crowley J (1992) Relative risk trees for censored survival data. Biometrics 48:411–425CrossRefPubMed

19.

Zhang H, Bonney G (2000) Use of classification trees for association studies. Genet Epidemiol 19:323–332CrossRefPubMed

20.

Province MA, Shannon WD, Rao DC (2001) Classification methods for confronting heterogeneity. Adv Genet 42:273–286CrossRefPubMed

21.

Shannon WD, Province MA, Rao DC (2001) Tree-based recursive partitioning methods for subdividing sibpairs into relatively more homogeneous subgroups. Genet Epidemiol 20:293–306CrossRefPubMed

22.

Lagerstedt Robinson K, Liu T, Vandrovcova J et al (2007) Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst 99:291–299CrossRefPubMed

23.

Raevaara TE, Korhonen MK, Lohi H et al (2005) Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology 129:537–549PubMed

24.

Therneau T, Atkinson E (1997) An introduction to recursive partitioning using the RPART routine. Mayo Clinic, Section of Statistics, Rochester

25.

Lin D, Wei L (1989) The robust inference for the cox proportional hazards model. J Am Stat Assoc 84:1074–1078CrossRef

26.

Whelan AJ, Bartsch D, Goodfellow PJ (1995) Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 333:975–977CrossRefPubMed

27.

Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489CrossRefPubMed

28.

Gu J, Gong Y, Huang M, Lu C, Spitz MR, Wu X (2007) Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis 28:350–355CrossRefPubMed

29.

Katayama H, Sasai K, Kawai H et al (2004) Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36:55–62CrossRefPubMed

30.

Coqueret O (2003) New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13:65–70CrossRefPubMed

31.

Sharma N, Timmers C, Trikha P, Saavedra HI, Obery A, Leone G (2006) Control of the p53–p21CIP1 Axis by E2f1, E2f2, and E2f3 is essential for G1/S progression and cellular transformation. J Biol Chem 281:36124–36131CrossRefPubMed

32.

Kruger S, Engel C, Bier A et al (2006) Absence of association between cyclin D1 (CCND1) G870A polymorphism and age of onset in hereditary nonpolyposis colorectal cancer. Cancer Lett 236:191–197CrossRefPubMed

33.

Bala S, Peltomaki P (2001) CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res 61:6042–6045PubMed

34.

Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J (1995) Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11:1005–1011PubMed

35.

Sawa H, Ohshima TA, Ukita H et al (1998) Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 16:1701–1712CrossRefPubMed

36.

Horne BD, Anderson JL, Carlquist JF et al (2005) Generating genetic risk scores from intermediate phenotypes for use in association studies of clinically significant endpoints. Ann Hum Genet 69:176–186CrossRefPubMed

37.

Wang W, Spitz MR, Yang H et al (2007) Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res 13:5974–5981CrossRefPubMed

Title: Genetic variants in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome
Authors: Jinyun Chen
Carol J. Etzel
Christopher I. Amos
Qing Zhang
Nancy Viscofsky
Noralane M. Lindor
Patrick M. Lynch
Marsha L. Frazier
Publication date: 01-11-2009
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 9/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-009-9416-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Experimental design

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2009

Legume intake and the risk of cancer: a multisite case–control study in Uruguay

Is the incidence of invasive vulvar cancer increasing in the United States?

International variation in the incidence of adult primary malignant neoplasms of the brain and central nervous system

Metformin use and prostate cancer in Caucasian men: results from a population-based case–control study

Factors related to second cancer screening practice in disease-free cervical cancer survivors

Menstrual and reproductive factors and pancreatic cancer in the SEARCH program of the IARC

Keynote webinar | Spotlight on antibody–drug conjugates in cancer